Last mentioned: Mar 5, 2026
Anticipated FDA Approval
Expected regulatory clearance for the first Evolysse filler products.
Commercial Launch
Planned U.S. launch of the Evolysse filler portfolio to aesthetic injectors.
Q4 Earnings
Company reports record revenue and market share for Jeuveau.
Filler Partnership
Evolus expands partnership with Symatese for the Evolysse dermal filler line.
Evolus, Inc. reported strong Q4 2025 results, driven by the continued market share expansion of its flagship neurotoxin, Jeuveau, and progress in its international rollout. The company remains on track to transform into a multi-product aesthetics platform with the anticipated 2026 launch of its Evolysse dermal filler line.
This page surfaces every story mentioning David Moatazedi across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where David Moatazedi was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |